D. Feng

发表

Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.

R. Miller, C. Strader, D. Macintyre, 2000, Bioorganic & medicinal chemistry letters.

In Situ Forming Injectable Thermoresponsive Hydrogels for Controlled Delivery of Biomacromolecules

S. Thayumanavan, J. Mu, K. Dutta, 2020, ACS omega.

An improved oxadiazole synthesis using peptide coupling reagents

G. Liang, D. Feng, 1996 .

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.

C. Strader, D. Macintyre, M. Forrest, 2000, Bioorganic & medicinal chemistry letters.

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

M. Erion, D. Kemp, S. Prahalada, 2017, Science.

Pharmacological AMPK activation induces transcriptional responses congruent to exercise in skeletal and cardiac muscle, adipose tissues and liver

M. Erion, D. Kemp, S. Souza, 2019, PloS one.

Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists

Margaret S. Wu, M. Erion, S. Hollingsworth, 2022, Nature Communications.

Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists

Margaret S. Wu, M. Erion, S. Hollingsworth, 2021, Nature communications.

A glucose-responsive insulin therapy protects animals against hypoglycemia.

Margaret S. Wu, M. Erion, D. Kelley, 2018, JCI Insight.

Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase.

D. Kemp, Gaochao Zhou, F. A. Romero, 2018, ACS medicinal chemistry letters.

Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index.

M. Erion, Fanyu Meng, S. Hollingsworth, 2022, Journal of medicinal chemistry.

A glucose-responsive insulin therapy protects animals against hypoglycemia.

Margaret S. Wu, M. Erion, D. Kelley, 2018, JCI insight.